Morphic Holding, Inc. is a biopharmaceutical company that develops integrin therapeutics using small molecules. Their lead product is MORF-057, an integrin inhibitor that is in Phase 1 clinical trial for inflammatory bowel disease. Morphic Holding, Inc. collaborates with several companies to develop integrin-based therapeutics for various disease treatments.